Investment Considerations Silo recently extended its option with the University of Maryland, Baltimore to explore arthritogenic joint-homing peptides and their use in arthritis-inflamed joints. In December 2021, the company announced the issuance of a patent relating to its University of Maryland, Baltimore licensed homing peptide for enhanced targeting of therapeutic agents to the central nervous … Continue reading “Silo Pharma Inc. (NASDAQ: SILO)”
Symbol | Release | Time |
---|---|---|
{{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |